NCT02309411 - EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2015

Primary Completion Date

April 5, 2017

Study Completion Date

April 5, 2017

Conditions

Venous Thromboembolism

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

With age and body-weight adjusted twice daily dosing of rivaroxaban as Oral Suspension to achieve a similar exposure as that observed in adults treated with 20 mg rivaroxaban once daily, and no other anticoagulant

Trial Locations (29)

1090

Vienna

1097

Budapest

3010

Bern

3052

Parkville

10126

Turin

20122

Milan

30322

Children's Healthcare of Atlanta, Atlanta

32504

Pensacola

32610

Gainesville

35128

Padua

46026

Valencia

46202

Indianapolis

60611

Chicago

117997

Moscow

197022

Saint Petersburg

603136

Nizhny Novgorod

5262000

Ramat Gan

9112001

Jerusalem

01227-200

São Paulo

Unknown

São Paulo

M5G 1X8

Toronto

157-8535

Setagaya City

6525 GA

Nijmegen

80-952

Gdansk

10-561

Olsztyn

08035

Barcelona

NE1 4LP

Newcastle upon Tyne

B4 6NH

Birmingham

CF14 4XW

Cardiff